Start the Phase 3 clinical program for denifanstat
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 22 Jan 2024
- Due
- 31 Dec 2024
- Delivered
- Q4 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“starting our Phase 3 program for development of denifanstat in NASH with related fibrosis, which we anticipate to begin in the second half of 2024.”
What we found
Evidence strength A What the grades mean
The company initiated its Phase 3 clinical program for denifanstat in the fourth quarter of 2024, meeting its commitment to begin the program in the second half of 2024.
-
A Sagimet Biosciences Inc. 8-K filed 2025-01-02
“Phase 3 program initiated with sites activated & patients pre - screened in 4Q2024” ✓ confirmed on the page
Market reaction: the shares moved +49.1% against the S&P 500 over the three sessions around the disclosure (31 Dec 2024 to 6 Jan 2025). What this measures
Checked 25 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Start
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Sagimet Biosciences Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-SGMT-000050 · Corrections policy